The N-Terminal HSDCIF Motif Is Required for Cell Surface Trafficking and Dimerization of Family B G Protein Coupled Receptor PAC1

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Yu, Rongjie ^a   Guo, Xiaoling ^a   Zhong, Jiaping ^a   Li, Mei ^a   Zeng, Zhixing ^a   Zhang, Huahua ^b  

^a JINAN UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL MIGRATION; CELL PROLIFERATION; CHO CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DELETION MUTANT; DIMERIZATION; FEMALE; HSDCIF MOTIF; IMMUNOFLUORESCENCE; NONHUMAN; PROTEIN MOTIF; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER TECHNIQUES; BLOTTING, WESTERN; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871354260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051811     Document Type: Article

References (34)

1. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166: 4-17.
2. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52: 269-324.
3. Laburthe M, Couvineau A, Tan V, (2007) Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28: 1631-1639.
4. Laburthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, et al. (1996) Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Ann N Y Acad Sci 805: 94-109.
5. Dickson L, Finlayson K, (2009) VPAC and PAC receptors: From ligands to function. Pharmacol Ther 121: 294-316.
6. Milligan G, (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66: 1-7.
7. Terrillon S, Bouvier M, (2004) Roles of G-protein-coupled receptor dimerization. EMBO Rep 5(1): 30-34.
8. Prinster SC, Hague C, Hall RA, (2005) Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57: 289-298.
9. Roed SN, Orgaard A, Jorgensen R, Meyts PD, (2012) Receptor Oligomerization in Family B1 of G-Protein-Coupled Receptors: Focus on BRET Investigations and the Link between GPCR Oligomerization and Binding Cooperativity. Front Endocrinol (Lausanne) 3: 62-66.
10. Gao F, Harikumar KG, Dong M, Lam PC, Sexton PM, et al. (2009) Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol Pharmacol 76: 264-274.
11. Harikumar KG, Morfis MM, Lisenbee CS, Sexton PM, Miller LJ, (2006) Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol Pharmacol 69: 363-373.
12. Langer I, Gaspard N, Robberecht P, (2006) Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2). Br J Pharmacol 148: 1051-1059.
13. Szidonya L, Cserzo M, Hunyady L, (2008) Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions. J Endocrinol 196: 435-453.
14. Yu R, Li J, Wang J, Liu X, Huang L, Ding Y, et al. (2010) The functional recombinant first extracellular (EC1) domain of PACAP receptor PAC1 normal form (PAC1-EC1(N)) recognizes selective ligands and stimulates the proliferation of PAC1-CHO cells. Neurosci Lett 480: 73-77.
15. Bourgault S, Vaudry D, Ségalas-Milazzo I, Guilhaudis L, Couvineau A, et al. (2009) Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem 52: 3308-3316.
16. Robberecht P, Gourlet P, De Neef P, Woussen-Colle MC, Vandermeers-Piret MC, et al. (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. Eur J Biochem 207: 239-246.
17. Aino H, Hashimoto H, Ogawa N, Nishino A, Yamamoto K, et al. (1995) Structure of the gene encoding the mouse pituitary adenylate cyclase-activating polypeptide receptor. Gene 164: 301-304.
18. Okazaki K, Kimura C, Kosaka T, Watanabe T, Ohkubo S, et al. (1992) Expression of human pituitary adenylate cyclase activating polypeptide (PACAP) cDNA in CHO cells and characterization of the products. FEBS Lett 298: 49-56.
19. Kerppola TK, (2006) Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nature Protocols 1: 1278-1286.
20. Harikumar KG, Pinon DI, Miller LJ, (2007) Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor. J Biol Chem 282: 30363-30372.
21. Yu R, Xie Q, Dai Y, Gao Y, Zhou T, et al. (2006) Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2. Peptides 27: 1359-1366.
22. Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, et al. (2009) Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Curr Med Chem 16: 4462-4480.
23. Lieu SN, Oh DS, Pisegna JR, Germano PM, (2006) Neuroendocrine tumors express PAC1 receptors. Ann N Y Acad Sci 1070: 399-404.
24. Lee JC, Cho YJ, Kim J, Kim N, Kang BG, et al. (2010) Region-specific changes in the immunoreactivity of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC2, and PAC1 receptor) in the aged rat brains. Brain Res 1351: 32-40.
25. Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, et al. (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470: 492-497.
26. Couvineau A, Rouyer-Fessard C, Laburthe M, (2004) Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor. Regul Pept 123: 181-185.
27. Langer I, Leroy K, Gaspard N, Brion JP, Robberecht P, (2008) Cell surface targeting of VPAC1 receptors: evidence for implication of a quality control system and the proteasome. Biochim Biophys Acta 1783: 1663-1672.
28. Hawtin SR, Simms J, Conner M, Lawson Z, Parslow RA, et al. (2006) Charged extracellular residues, conserved throughout a G-protein-coupled receptor family, are required for ligand binding, receptor activation, and cell-surface expression. J Biol Chem 281: 38478-38488.
29. Asmann YW, Dong M, Ganguli S, Hadac EM, Miller LJ, (2000) Structural insights into the amino-terminus of the secretin receptor: I. Status of cysteine and cystine residues. Mol Pharmacol 58: 911-919.
30. Lisenbee CS, Dong M, Miller LJ, (2005) Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor. J Biol Chem 280: 12330-12338.
31. Gurevich VV, Gurevich EV, (2008) GPCR monomers and oligomers: it takes all kinds. Trends Neurosci 31: 74-81.
32. Romano C, Yang WL, O'Malley KL, (1996) Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 271: 28612-28616.
33. Yu R, Wang J, Li J, Wang Y, Zhang H, et al. (2010) A novel cyclopeptide from the cyclization of PACAP(1-5) with potent activity towards PAC1 attenuates STZ-induced diabetes. Peptides 31: 1062-1067.
34. Boronkai A, Brubel R, Racz B, Tamas A, Kiss P, et al. (2009) Effects of pituitary adenylate cyclase activating polypeptide on the survival and signal transduction pathways in human choriocarcinoma cells. Ann N Y Acad Sci 1163: 353-357.